<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326986</url>
  </required_header>
  <id_info>
    <org_study_id>7252-001</org_study_id>
    <secondary_id>2017-003407-22</secondary_id>
    <secondary_id>MK-7252-001</secondary_id>
    <nct_id>NCT03326986</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)</brief_title>
  <official_title>A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of
      MK-7252 in healthy adults. Participants receive ascending doses of MK-7252 over five
      treatment periods. Each treatment period is separated by a 7-day washout period.

      Upon review of the interim safety and preliminary PK data of human exposure to date, Protocol
      Amendment 3 includes a third panel of participants, Panel C, to assess the PK of higher doses
      of MK-7252 and to assess the food effect of MK-7252.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three panels (Panels A, B, and C) of 8 healthy participants (n=6 MK-7252, n=2 placebo) are
      enrolled. In Panels A and B, participants will alternately receive single rising doses of
      MK-7252 or placebo for 5 treatment periods. In Panel C, participants will receive single
      rising doses of MK-7252 or placebo for up to 5 treatment periods. All doses in Panels A and B
      will be administered in the fasted state during the 5 treatment periods. Doses in Panel C
      will be administered in a fasted state in treatment periods 1 through 4 and the treatment
      period 1 dose will be repeated in a fed state during treatment period 5. Panel A will begin
      first. At least 3 days will elapse before participants in Panel B will receive the next
      higher dose. For all panels, there will be at least 7 days washout between treatment periods
      for any given participant. Participants may only be enrolled in one panel of the study. The
      planned dose levels may be adjusted downward or replaced based on evaluation of safety,
      tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment
      periods. All participants in the treatment periods of all panels (with exception of 120 mg
      fasted/fed periods in Panel C) will be randomly assigned to either study drug or placebo;
      that is a participant could be assigned to receive study drug in one period and placebo in
      another. As per the protocol allocation plan, the same participants in Panel C will receive
      120 mg MK-7252 in a fasted and fed state. In addition, during any of the treatment periods if
      a participant demonstrates change in any one of the protocol-defined parameters lasting ≥2
      hours, dose escalation in that participant will be halted and the participant may be
      withdrawn from the study or re-challenged at same dose or at a lower or divided dose.
      Participants that meet criteria listed will be followed up until parameters no longer meet
      stopping rule criteria.

      During the study, participants in Panel A were planned to receive placebo, 1 mg, 6 mg, 24 mg,
      72 mg and 108 mg, all in a fasted state in 5 periods. Participants in Panel B were planned to
      receive placebo, 3 mg, 12 mg, 48 mg, 72 mg and 162 mg, all in a fasted state in 5 periods.
      All periods in Panels A and B were conducted. Participants in Panel C were planned to receive
      placebo fasted, placebo fed, 120 mg fasted, 240 mg fasted, 360 mg fasted, 540 mg fasted, and
      120 mg fed in 5 periods. Periods 4 and 5 were not conducted and, as a result, the 240 mg
      fasted, 360 mg fasted, 540 mg fasted, 120 mg fed, and placebo fed doses were not
      administered. A 180 mg fasted dose was added during Period 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Actual">December 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 17, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Adverse Event (AE)</measure>
    <time_frame>Up to approximately 21 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 19 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞)</measure>
    <time_frame>Predose (Day 1) and 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-∞ reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. Pharmacokinetic (PK) results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-∞ following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-∞ in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr)</measure>
    <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, and 24 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-24hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr)</measure>
    <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, and 12 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-12hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast)</measure>
    <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUClast reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUClast following a high-fat breakfast (fed state) was planned to be compared to the plasma AUClast in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Maximal Plasma Concentration (Cmax)</measure>
    <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Cmax reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Cmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Cmax in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr)</measure>
    <time_frame>12 hours postdose</time_frame>
    <description>Blood samples were obtained 12 hours postdose to calculate the plasma MK-7252 C12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C12hr values less than the lower limit of quantification (LLOQ), the C12hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C12hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr)</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>Blood samples were obtained 24 hours postdose to calculate the plasma MK-7252 C24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C24hr values less than the lower limit of quantification (LLOQ), the C24hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C24hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Time to Reach Maximal Concentration (Tmax)</measure>
    <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Tmax. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Tmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Tmax in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MK-7252 Apparent Terminal Half-life (t½)</measure>
    <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
    <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 t½ reported as Geometric Mean with Percent Geometric Coefficient of Variation. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma t½ following a high-fat breakfast (fed state) was planned to be compared to the plasma t½ in the fasted stated in Panel C, the fed state dose was not administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours</measure>
    <time_frame>Baseline (Predose Day 1) and 4 hours postdose</time_frame>
    <description>Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 4 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours</measure>
    <time_frame>Baseline (Predose Day 1) and 24 hours postdose</time_frame>
    <description>Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 24 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours</measure>
    <time_frame>Baseline (Predose Day 1) and 4 hours postdose</time_frame>
    <description>Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 4 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours</measure>
    <time_frame>Baseline (Predose Day 1) and 24 hours postdose</time_frame>
    <description>Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 24 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate (HR) at 4 Hours</measure>
    <time_frame>Baseline (Predose Day 1) and 4 hours postdose</time_frame>
    <description>Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 4 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate (HR) at 24 Hours</measure>
    <time_frame>Baseline (Predose Day 1) and 24 hours postdose</time_frame>
    <description>Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 24 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-7252</intervention_name>
    <description>1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL</description>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL</description>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants of non-childbearing potential (Note: If postmenopausal
             female: participant is without menses for at least 1 year and has a documented
             follicle stimulating hormone [FSH] level in the postmenopausal range at pre-trial
             [screening] - OR - If surgically sterile female: participant is status post
             hysterectomy, oophorectomy or tubal ligation.)

          -  Body Mass Index (BMI) between 18.5 and 32 kg/m^2, inclusive. BMI = weight (kg)/height
             (m)^2.

          -  While in semi-recumbent position, has a systolic blood pressure ≤140 mmHg and
             diastolic blood pressure ≤90 mm Hg and a respiratory rate ≤20 breaths/min at the
             pre-study (screening) visit and prior to randomization.

          -  Judged to be in good health based on medical history, physical examination, vital sign
             measurements and electrocardiogram (ECG) performed prior to randomization.

          -  Non-smoker and/or has not used nicotine or nicotine-containing products (e.g.,
             nicotine patch) for at least approximately 3 months.

        Exclusion Criteria:

          -  Mentally or legally incapacitated, has significant emotional problems at the time of
             pretrial (screening) visit or expected during the conduct of the study or has a
             history of clinically significant psychiatric disorder of the last 5 years.

          -  History of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, genitourinary or major
             neurological (including stroke and chronic seizures) abnormalities or diseases.

          -  History of liver disease (chronic hepatitis, cirrhosis, etc.).

          -  History of cancer (malignancy). Exceptions include adequately treated non-melanomatous
             skin carcinoma or carcinoma in situ of the cervix and other malignancies which have
             been successfully treated ≥10 years prior to the pre-study (screening) visit.

          -  History of significant multiple and/or severe allergies (e.g. food, drug, latex
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.
             systemic allergic reaction) to prescription or non-prescription drugs or food.

          -  Tests positive for hepatitis B surface antigen, hepatitis C antibodies or human
             immunodeficiency virus (HIV).

          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4
             weeks prior to the pre-study (screening) visit.

          -  Participated in another investigational study within 4 weeks (or 5 half-lives),
             whichever is greater, prior to the pre-study (screening) visit.

          -  QTc interval ≥470 msec (for males) and ≥480 msec (for females).

          -  Taken a Proton Pump Inhibitor (PPI) during the 5 days prior to start of study
             treatment.

          -  Unable to refrain from or anticipates the use of any medication, including
             prescription and non-prescription drugs or herbal remedies beginning approximately 2
             weeks (or 5 half-lives) prior to administration of the initial dose of study drug,
             throughout the study (including washout intervals between treatment periods), until
             the post-study visit.

          -  Consumes &gt;3 glasses of alcoholic beverages (1 glass is approximately equivalent to:
             beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1
             ounce]) per day.

          -  Consumes excessive amounts, defined as &gt;6 servings (1 serving is approximately
             equivalent to 120 mg of caffeine) of coffee, tea, cola, energy-drinks, or other
             caffeinated beverages per day.

          -  Regular user of cannabis, any illicit drugs or has a history of drug (including
             alcohol) abuse within approximately 1 year. Participants must have a negative result
             for urine drug screen test prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent ( Site 0001)</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <results_first_submitted>November 21, 2019</results_first_submitted>
  <results_first_submitted_qc>December 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2020</results_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03326986/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants in Panels A and B received a single-rising dose of MK-7252 or placebo in 5 alternating dosing periods. Participants in Panel C received a single-rising dose of MK-7252 or placebo in 3/5 planned periods (P). A 180 mg dose was added (P3). P4-5 were not run so the 240, 360, 540, and 120 mg fed and placebo fed doses were not given.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panel A</title>
          <description>Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (1 mg, 6 mg, 24 mg, 72 mg, or 108 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel B.</description>
        </group>
        <group group_id="P2">
          <title>Panel B</title>
          <description>Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (3 mg, 12 mg, 48 mg, 72 mg, or 162 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel A.</description>
        </group>
        <group group_id="P3">
          <title>Panel C</title>
          <description>Within each of 3 single dose treatment periods, 6 participants received a single dose of MK-7252 (120 mg or 180 mg) and 2 participants received placebo in a fasted state. The 120 mg dose of MK-7252 was administered in the first 2 periods and the 180 mg dose was administered in the third period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Panel A</title>
          <description>Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (1 mg, 6 mg, 24 mg, 72 mg, or 108 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel B.</description>
        </group>
        <group group_id="B2">
          <title>Panel B</title>
          <description>Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-7252 (3 mg, 12 mg, 48 mg, 72 mg, or 162 mg) and 2 participants received placebo in a fasted state. Dosing periods alternated with Panel A.</description>
        </group>
        <group group_id="B3">
          <title>Panel C</title>
          <description>Within each of 3 single dose treatment periods, 6 participants received a single dose of MK-7252 (120 mg or 180 mg) and 2 participants received placebo in a fasted state. The 120 mg dose of MK-7252 was administered in the first 2 periods and the 180 mg dose was administered in the third period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="10.2"/>
                    <measurement group_id="B2" value="35.0" spread="9.5"/>
                    <measurement group_id="B3" value="34.4" spread="9.3"/>
                    <measurement group_id="B4" value="34.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Adverse Event (AE)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.</description>
        <time_frame>Up to approximately 21 weeks</time_frame>
        <population>All participants who received at least 1 dose of study treatment and experienced an AE during the study period</population>
        <group_list>
          <group group_id="O1">
            <title>MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>MK-7252 120 mg</title>
            <description>Single oral dose of 120 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>MK-7252 180 mg</title>
            <description>Single oral dose of 180 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Adverse Event (AE)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.</description>
          <population>All participants who received at least 1 dose of study treatment and experienced an AE during the study period</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Treatment Due to an AE</title>
        <description>An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.</description>
        <time_frame>Up to approximately 19 weeks</time_frame>
        <population>All participants who received at least 1 dose of study treatment and discontinued during the study period</population>
        <group_list>
          <group group_id="O1">
            <title>MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>MK-7252 120 mg</title>
            <description>Single oral dose of 120 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>MK-7252 180 mg</title>
            <description>Single oral dose of 180 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Treatment Due to an AE</title>
          <description>An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.</description>
          <population>All participants who received at least 1 dose of study treatment and discontinued during the study period</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-∞ reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. Pharmacokinetic (PK) results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-∞ following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-∞ in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1) and 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4-5 of Panel C were not conducted; the planned 120 mg fed dose (P 5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Area Under the Concentration-Time Curve From Zero to Infinity (AUC0-∞)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-∞ reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. Pharmacokinetic (PK) results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-∞ following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-∞ in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4-5 of Panel C were not conducted; the planned 120 mg fed dose (P 5) was not administered.</population>
          <units>hr•nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Geometric mean and 95% confidence interval were not calculated for the 1 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the AUC0-∞ at this dose level.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Geometric mean and 95% confidence interval were not calculated for the 3 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the AUC0-∞ at this dose level.</measurement>
                    <measurement group_id="O3" value="288" lower_limit="195" upper_limit="427"/>
                    <measurement group_id="O4" value="583" lower_limit="394" upper_limit="862"/>
                    <measurement group_id="O5" value="1190" lower_limit="805" upper_limit="1750"/>
                    <measurement group_id="O6" value="2040" lower_limit="1390" upper_limit="3000"/>
                    <measurement group_id="O7" value="5090" lower_limit="3460" upper_limit="7490"/>
                    <measurement group_id="O8" value="3500" lower_limit="2380" upper_limit="5160"/>
                    <measurement group_id="O9" value="6680" lower_limit="4530" upper_limit="9840"/>
                    <measurement group_id="O10" value="9840" lower_limit="6690" upper_limit="14500"/>
                    <measurement group_id="O11" value="7260" lower_limit="4930" upper_limit="10700"/>
                    <measurement group_id="O12" value="5520" lower_limit="3720" upper_limit="8170"/>
                    <measurement group_id="O13" value="10300" lower_limit="6970" upper_limit="15300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-24hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, and 24 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Area Under the Concentration-Time Curve From Zero to 24 Hours Postdose (AUC0-24hr)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-24hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>hr•nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="32.4" upper_limit="70.4"/>
                    <measurement group_id="O2" value="122" lower_limit="82.4" upper_limit="179"/>
                    <measurement group_id="O3" value="279" lower_limit="189" upper_limit="411"/>
                    <measurement group_id="O4" value="559" lower_limit="379" upper_limit="824"/>
                    <measurement group_id="O5" value="1150" lower_limit="781" upper_limit="1700"/>
                    <measurement group_id="O6" value="2030" lower_limit="1380" upper_limit="3000"/>
                    <measurement group_id="O7" value="5210" lower_limit="3530" upper_limit="7680"/>
                    <measurement group_id="O8" value="3490" lower_limit="2370" upper_limit="5150"/>
                    <measurement group_id="O9" value="6420" lower_limit="4350" upper_limit="9470"/>
                    <measurement group_id="O10" value="9530" lower_limit="6460" upper_limit="14100"/>
                    <measurement group_id="O11" value="7240" lower_limit="4900" upper_limit="10700"/>
                    <measurement group_id="O12" value="5510" lower_limit="3710" upper_limit="8200"/>
                    <measurement group_id="O13" value="10300" lower_limit="6910" upper_limit="15300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-12hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, and 12 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Area Under the Concentration-Time Curve From Zero to 12 Hours Postdose (AUC0-12hr)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUC0-12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUC0-12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma AUC0-12hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>hr•nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="32.5" upper_limit="70.4"/>
                    <measurement group_id="O2" value="121" lower_limit="82.5" upper_limit="179"/>
                    <measurement group_id="O3" value="278" lower_limit="189" upper_limit="409"/>
                    <measurement group_id="O4" value="558" lower_limit="379" upper_limit="822"/>
                    <measurement group_id="O5" value="1140" lower_limit="775" upper_limit="1680"/>
                    <measurement group_id="O6" value="2020" lower_limit="1370" upper_limit="2980"/>
                    <measurement group_id="O7" value="5130" lower_limit="3480" upper_limit="7540"/>
                    <measurement group_id="O8" value="3450" lower_limit="2340" upper_limit="5070"/>
                    <measurement group_id="O9" value="6220" lower_limit="4220" upper_limit="9160"/>
                    <measurement group_id="O10" value="9240" lower_limit="6270" upper_limit="13600"/>
                    <measurement group_id="O11" value="7170" lower_limit="4860" upper_limit="10600"/>
                    <measurement group_id="O12" value="5480" lower_limit="3690" upper_limit="8130"/>
                    <measurement group_id="O13" value="10200" lower_limit="6840" upper_limit="15100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUClast reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUClast following a high-fat breakfast (fed state) was planned to be compared to the plasma AUClast in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Area Under the Concentration-Time Curve From Zero to Last Measurable Concentration (AUClast)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 AUClast reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma AUClast following a high-fat breakfast (fed state) was planned to be compared to the plasma AUClast in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>hr•nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" lower_limit="26.0" upper_limit="57.6"/>
                    <measurement group_id="O2" value="101" lower_limit="68.1" upper_limit="151"/>
                    <measurement group_id="O3" value="250" lower_limit="168" upper_limit="371"/>
                    <measurement group_id="O4" value="543" lower_limit="365" upper_limit="808"/>
                    <measurement group_id="O5" value="1130" lower_limit="757" upper_limit="1680"/>
                    <measurement group_id="O6" value="2030" lower_limit="1360" upper_limit="3020"/>
                    <measurement group_id="O7" value="5170" lower_limit="3470" upper_limit="7690"/>
                    <measurement group_id="O8" value="3420" lower_limit="2300" upper_limit="5090"/>
                    <measurement group_id="O9" value="6330" lower_limit="4250" upper_limit="9420"/>
                    <measurement group_id="O10" value="9750" lower_limit="6550" upper_limit="14500"/>
                    <measurement group_id="O11" value="7250" lower_limit="4860" upper_limit="10800"/>
                    <measurement group_id="O12" value="5500" lower_limit="3670" upper_limit="8260"/>
                    <measurement group_id="O13" value="10300" lower_limit="6860" upper_limit="15500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Maximal Plasma Concentration (Cmax)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Cmax reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Cmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Cmax in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Maximal Plasma Concentration (Cmax)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Cmax reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Cmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Cmax in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" lower_limit="15.4" upper_limit="29.4"/>
                    <measurement group_id="O2" value="51.7" lower_limit="37.4" upper_limit="71.5"/>
                    <measurement group_id="O3" value="117" lower_limit="84.6" upper_limit="162"/>
                    <measurement group_id="O4" value="220" lower_limit="159" upper_limit="305"/>
                    <measurement group_id="O5" value="447" lower_limit="323" upper_limit="618"/>
                    <measurement group_id="O6" value="830" lower_limit="600" upper_limit="1150"/>
                    <measurement group_id="O7" value="1860" lower_limit="1340" upper_limit="2570"/>
                    <measurement group_id="O8" value="1380" lower_limit="997" upper_limit="1910"/>
                    <measurement group_id="O9" value="2290" lower_limit="1660" upper_limit="3170"/>
                    <measurement group_id="O10" value="3380" lower_limit="2440" upper_limit="4670"/>
                    <measurement group_id="O11" value="3160" lower_limit="2280" upper_limit="4380"/>
                    <measurement group_id="O12" value="2550" lower_limit="1820" upper_limit="3580"/>
                    <measurement group_id="O13" value="3880" lower_limit="2760" upper_limit="5440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr)</title>
        <description>Blood samples were obtained 12 hours postdose to calculate the plasma MK-7252 C12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C12hr values less than the lower limit of quantification (LLOQ), the C12hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C12hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>12 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Plasma Concentration at 12 Hours Postdose (C12hr)</title>
          <description>Blood samples were obtained 12 hours postdose to calculate the plasma MK-7252 C12hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C12hr values less than the lower limit of quantification (LLOQ), the C12hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C12hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C12hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 1 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 3 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 6 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C12hr values for the 12 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O5" value="2.19" lower_limit="1.17" upper_limit="4.10"/>
                    <measurement group_id="O6" value="2.95" lower_limit="1.57" upper_limit="5.51"/>
                    <measurement group_id="O7" value="11.7" lower_limit="6.29" upper_limit="21.7"/>
                    <measurement group_id="O8" value="7.06" lower_limit="3.80" upper_limit="13.1"/>
                    <measurement group_id="O9" value="21.0" lower_limit="11.2" upper_limit="39.2"/>
                    <measurement group_id="O10" value="31.8" lower_limit="17.0" upper_limit="59.6"/>
                    <measurement group_id="O11" value="10.4" lower_limit="5.59" upper_limit="19.3"/>
                    <measurement group_id="O12" value="7.16" lower_limit="3.76" upper_limit="13.7"/>
                    <measurement group_id="O13" value="16.7" lower_limit="8.77" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr)</title>
        <description>Blood samples were obtained 24 hours postdose to calculate the plasma MK-7252 C24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C24hr values less than the lower limit of quantification (LLOQ), the C24hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C24hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>24 hours postdose</time_frame>
        <population>All participants who received study treatment, complied with the protocol to ensure data were likely to exhibit effects of treatment according to the scientific model, and had data available for endpoint. Periods 4-5 of Panel C was not conducted and planned 120 mg fed dose not administered. Analysis was not performed due to values being &lt;LLOQ.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Plasma Concentration at 24 Hours Postdose (C24hr)</title>
          <description>Blood samples were obtained 24 hours postdose to calculate the plasma MK-7252 C24hr reported as back-transformed least squares mean and confidence interval calculated using a linear mixed effects model performed on natural log-transformed values. For participants in a given dose that had C24hr values less than the lower limit of quantification (LLOQ), the C24hr value was imputed as half x LLOQ. The LLOQ was 2.74 nmol/L. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma C24hr following a high-fat breakfast (fed state) was planned to be compared to the plasma C24hr in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment, complied with the protocol to ensure data were likely to exhibit effects of treatment according to the scientific model, and had data available for endpoint. Periods 4-5 of Panel C was not conducted and planned 120 mg fed dose not administered. Analysis was not performed due to values being &lt;LLOQ.</population>
          <units>nmol/L</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 1 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 3 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 6 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 12 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 24 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 48 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 72 mg dose in level in Panel A being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 72 mg dose level in Panel B being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 108 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 162 mg dose level being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 120 mg dose level in Panel C Period 1 being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 120 mg dose level in Panel C Period 2 being below the LLOQ (2.74 nmol/L).</measurement>
                    <measurement group_id="O13" value="NA" lower_limit="NA" upper_limit="NA">Geometric least squares mean and 90% confidence interval were not calculated due to C24hr values for the 180 mg dose level in Panel C Period 3 being below the LLOQ (2.74 nmol/L).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Time to Reach Maximal Concentration (Tmax)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Tmax. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Tmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Tmax in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Time to Reach Maximal Concentration (Tmax)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 Tmax. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma Tmax following a high-fat breakfast (fed state) was planned to be compared to the plasma Tmax in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O9" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O10" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O11" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O12" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O13" value="1.00" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MK-7252 Apparent Terminal Half-life (t½)</title>
        <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 t½ reported as Geometric Mean with Percent Geometric Coefficient of Variation. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma t½ following a high-fat breakfast (fed state) was planned to be compared to the plasma t½ in the fasted stated in Panel C, the fed state dose was not administered.</description>
        <time_frame>Predose (Day 1), 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 48, and 72 hours postdose</time_frame>
        <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>MK-7252 Apparent Terminal Half-life (t½)</title>
          <description>Blood samples were obtained predose (Day 1) and at designated times postdose to calculate the plasma MK-7252 t½ reported as Geometric Mean with Percent Geometric Coefficient of Variation. PK results were reported by dose taken in Panels A and B. For Panel C, PK results were reported by dose taken and by individual period. Periods in a panel were not conducted if it became evident that exposures at the escalated dosing would not adequately reach the projected PK target. Although the plasma t½ following a high-fat breakfast (fed state) was planned to be compared to the plasma t½ in the fasted stated in Panel C, the fed state dose was not administered.</description>
          <population>All participants who received study treatment and complied with the protocol sufficiently to ensure that data were likely to exhibit the effects of the treatment, according to the underlying scientific model and had data available for endpoint. Periods (P) 4 and 5 of Panel C were not conducted; the planned 120 mg fed dose (P5) was not administered.</population>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Geometric mean and 95% confidence interval were not calculated for the 1 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the t½ at this dose level.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Geometric mean and 95% confidence interval were not calculated for the 3 mg dose: there were insufficient data points above the lower limit of quantification of the assay (2.74 nM) to calculate the t½ at this dose level.</measurement>
                    <measurement group_id="O3" value="1.29" spread="12.18"/>
                    <measurement group_id="O4" value="1.34" spread="14.99"/>
                    <measurement group_id="O5" value="1.60" spread="19.86"/>
                    <measurement group_id="O6" value="1.35" spread="9.93"/>
                    <measurement group_id="O7" value="1.76" spread="60.34"/>
                    <measurement group_id="O8" value="1.59" spread="19.54"/>
                    <measurement group_id="O9" value="3.09" spread="81.14"/>
                    <measurement group_id="O10" value="5.97" spread="92.18"/>
                    <measurement group_id="O11" value="1.96" spread="52.80"/>
                    <measurement group_id="O12" value="2.40" spread="71.03"/>
                    <measurement group_id="O13" value="2.90" spread="152.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours</title>
        <description>Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 4 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.</description>
        <time_frame>Baseline (Predose Day 1) and 4 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study treatment and had SBP assessments at baseline and 4 hours postdose</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) at 4 Hours</title>
          <description>Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 4 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.</description>
          <population>All participants who received at least 1 dose of study treatment and had SBP assessments at baseline and 4 hours postdose</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Measurement sets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Measurement sets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.61" spread="1.94"/>
                    <measurement group_id="O2" value="1.56" spread="2.57"/>
                    <measurement group_id="O3" value="0.50" spread="2.66"/>
                    <measurement group_id="O4" value="4.39" spread="2.08"/>
                    <measurement group_id="O5" value="6.78" spread="3.71"/>
                    <measurement group_id="O6" value="12.17" spread="1.57"/>
                    <measurement group_id="O7" value="14.00" spread="4.28"/>
                    <measurement group_id="O8" value="9.83" spread="0.84"/>
                    <measurement group_id="O9" value="11.28" spread="1.90"/>
                    <measurement group_id="O10" value="5.33" spread="2.15"/>
                    <measurement group_id="O11" value="18.17" spread="7.65"/>
                    <measurement group_id="O12" value="3.80" spread="4.15"/>
                    <measurement group_id="O13" value="6.13" spread="4.52"/>
                    <measurement group_id="O14" value="3.22" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours</title>
        <description>Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 24 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.</description>
        <time_frame>Baseline (Predose Day 1) and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study treatment and had SBP assessments at baseline and 24 hours postdose</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours</title>
          <description>Assessment of the change from baseline in SBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 SBP measurements: baseline and 24 hours postdose. SBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in SBP and a negative number indicates a decrease in SBP.</description>
          <population>All participants who received at least 1 dose of study treatment and had SBP assessments at baseline and 24 hours postdose</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Measurement sets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Measurement sets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="3.40"/>
                    <measurement group_id="O2" value="0.89" spread="3.00"/>
                    <measurement group_id="O3" value="-1.11" spread="1.56"/>
                    <measurement group_id="O4" value="-3.56" spread="2.47"/>
                    <measurement group_id="O5" value="-0.17" spread="2.75"/>
                    <measurement group_id="O6" value="-0.56" spread="2.48"/>
                    <measurement group_id="O7" value="7.56" spread="1.32"/>
                    <measurement group_id="O8" value="3.56" spread="1.81"/>
                    <measurement group_id="O9" value="0.22" spread="3.36"/>
                    <measurement group_id="O10" value="3.17" spread="1.61"/>
                    <measurement group_id="O11" value="4.67" spread="3.51"/>
                    <measurement group_id="O12" value="-0.13" spread="4.98"/>
                    <measurement group_id="O13" value="7.27" spread="3.86"/>
                    <measurement group_id="O14" value="5.84" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours</title>
        <description>Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 4 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.</description>
        <time_frame>Baseline (Predose Day 1) and 4 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study treatment and had DBP assessments at baseline and 4 hours postdose</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure (DBP) at 4 Hours</title>
          <description>Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 4 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.</description>
          <population>All participants who received at least 1 dose of study treatment and had DBP assessments at baseline and 4 hours postdose</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Measurement sets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Measurement sets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="1.77"/>
                    <measurement group_id="O2" value="1.61" spread="1.06"/>
                    <measurement group_id="O3" value="0.33" spread="1.88"/>
                    <measurement group_id="O4" value="2.28" spread="3.24"/>
                    <measurement group_id="O5" value="6.33" spread="1.55"/>
                    <measurement group_id="O6" value="6.22" spread="1.56"/>
                    <measurement group_id="O7" value="5.50" spread="2.03"/>
                    <measurement group_id="O8" value="7.28" spread="2.24"/>
                    <measurement group_id="O9" value="4.61" spread="1.24"/>
                    <measurement group_id="O10" value="5.33" spread="1.43"/>
                    <measurement group_id="O11" value="5.28" spread="1.24"/>
                    <measurement group_id="O12" value="11.27" spread="3.12"/>
                    <measurement group_id="O13" value="5.67" spread="1.96"/>
                    <measurement group_id="O14" value="0.61" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours</title>
        <description>Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 24 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.</description>
        <time_frame>Baseline (Predose Day 1) and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study treatment and had DBP assessments at baseline and 24 hours postdose</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours</title>
          <description>Assessment of the change from baseline in DBP was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 DBP measurements: baseline and 24 hours postdose. DBP results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in DBP and a negative number indicates a decrease in DBP.</description>
          <population>All participants who received at least 1 dose of study treatment and had DBP assessments at baseline and 24 hours postdose</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Measurement sets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Measurement sets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="1.31"/>
                    <measurement group_id="O2" value="2.78" spread="3.13"/>
                    <measurement group_id="O3" value="-2.67" spread="2.86"/>
                    <measurement group_id="O4" value="-3.33" spread="2.23"/>
                    <measurement group_id="O5" value="2.33" spread="1.69"/>
                    <measurement group_id="O6" value="-1.11" spread="2.03"/>
                    <measurement group_id="O7" value="2.11" spread="1.91"/>
                    <measurement group_id="O8" value="1.72" spread="1.62"/>
                    <measurement group_id="O9" value="-0.78" spread="2.49"/>
                    <measurement group_id="O10" value="4.11" spread="1.89"/>
                    <measurement group_id="O11" value="1.28" spread="1.59"/>
                    <measurement group_id="O12" value="4.00" spread="1.15"/>
                    <measurement group_id="O13" value="4.73" spread="1.16"/>
                    <measurement group_id="O14" value="1.99" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate (HR) at 4 Hours</title>
        <description>Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 4 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.</description>
        <time_frame>Baseline (Predose Day 1) and 4 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study treatment and had HR assessments at baseline and 4 hours postdose</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate (HR) at 4 Hours</title>
          <description>Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 4 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.</description>
          <population>All participants who received at least 1 dose of study treatment and had HR assessments at baseline and 4 hours postdose</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Measurement sets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Measurement sets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.22" spread="1.82"/>
                    <measurement group_id="O2" value="-0.28" spread="2.66"/>
                    <measurement group_id="O3" value="-1.22" spread="1.68"/>
                    <measurement group_id="O4" value="-0.89" spread="1.76"/>
                    <measurement group_id="O5" value="0.22" spread="0.88"/>
                    <measurement group_id="O6" value="0.17" spread="1.72"/>
                    <measurement group_id="O7" value="6.83" spread="7.05"/>
                    <measurement group_id="O8" value="2.28" spread="2.99"/>
                    <measurement group_id="O9" value="0.83" spread="2.21"/>
                    <measurement group_id="O10" value="1.33" spread="2.10"/>
                    <measurement group_id="O11" value="2.17" spread="6.07"/>
                    <measurement group_id="O12" value="-1.53" spread="1.36"/>
                    <measurement group_id="O13" value="1.27" spread="2.15"/>
                    <measurement group_id="O14" value="-1.27" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate (HR) at 24 Hours</title>
        <description>Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 24 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.</description>
        <time_frame>Baseline (Predose Day 1) and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study treatment and had HR assessments at baseline and 24 hours postdose</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A MK-7252 1 mg</title>
            <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Panel B MK-7252 3 mg</title>
            <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O3">
            <title>Panel A MK-7252 6 mg</title>
            <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O4">
            <title>Panel B MK-7252 12 mg</title>
            <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O5">
            <title>Panel A MK-7252 24 mg</title>
            <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O6">
            <title>Panel B MK-7252 48 mg</title>
            <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O7">
            <title>Panel A MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered in Panel A in a fasted state</description>
          </group>
          <group group_id="O8">
            <title>Panel B MK-7252 72 mg</title>
            <description>Single oral dose of 72 mg MK-7252 administered Panel B in a fasted state</description>
          </group>
          <group group_id="O9">
            <title>Panel A MK-7252 108 mg</title>
            <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O10">
            <title>Panel B MK-7252 162 mg</title>
            <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
          </group>
          <group group_id="O11">
            <title>Panel C MK-7252 120 mg Period 1</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 1 in a fasted state</description>
          </group>
          <group group_id="O12">
            <title>Panel C MK-7252 120 mg Period 2</title>
            <description>Single oral dose of 120 mg MK-7252 administered in Panel C Period 2 in a fasted state</description>
          </group>
          <group group_id="O13">
            <title>Panel C MK-7252 180 mg Period 3</title>
            <description>Single oral dose of 180 mg MK-7252 administered in Panel C Period 3 in a fasted state</description>
          </group>
          <group group_id="O14">
            <title>Placebo</title>
            <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate (HR) at 24 Hours</title>
          <description>Assessment of the change from baseline in HR was obtained using a validated, semi-automated oscillometric device. Baseline was defined as the average of predose measurements. A measurement set was considered 2 HR measurements: baseline and 24 hours postdose. HR results are reported by dose taken. Placebo measurements are pooled over periods across panels. A positive number indicates an increase in HR and a negative number indicates a decrease in HR.</description>
          <population>All participants who received at least 1 dose of study treatment and had HR assessments at baseline and 24 hours postdose</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Measurement sets</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Measurement sets</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="5"/>
                <count group_id="O13" value="5"/>
                <count group_id="O14" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" spread="2.01"/>
                    <measurement group_id="O2" value="2.72" spread="2.03"/>
                    <measurement group_id="O3" value="1.83" spread="1.38"/>
                    <measurement group_id="O4" value="3.89" spread="1.55"/>
                    <measurement group_id="O5" value="2.89" spread="1.19"/>
                    <measurement group_id="O6" value="1.67" spread="1.41"/>
                    <measurement group_id="O7" value="2.94" spread="1.73"/>
                    <measurement group_id="O8" value="2.17" spread="2.15"/>
                    <measurement group_id="O9" value="-0.61" spread="1.46"/>
                    <measurement group_id="O10" value="2.67" spread="2.18"/>
                    <measurement group_id="O11" value="-0.72" spread="2.53"/>
                    <measurement group_id="O12" value="1.40" spread="1.26"/>
                    <measurement group_id="O13" value="2.33" spread="1.13"/>
                    <measurement group_id="O14" value="2.23" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 21 weeks</time_frame>
      <desc>The safety population includes all participants who received at least 1 dose of study treatment. Adverse events are reported by dose taken at time of event and not by panel or period. Post-study adverse events were pooled across all arms in the study (MK-7252 and placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-7252 1 mg</title>
          <description>Single oral dose of 1 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E2">
          <title>MK-7252 3 mg</title>
          <description>Single oral dose of 3 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E3">
          <title>MK-7252 6 mg</title>
          <description>Single oral dose of 6 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E4">
          <title>MK-7252 12 mg</title>
          <description>Single oral dose of 12 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E5">
          <title>MK-7252 24 mg</title>
          <description>Single oral dose of 24 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E6">
          <title>MK-7252 48 mg</title>
          <description>Single oral dose of 48 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E7">
          <title>MK-7252 72 mg</title>
          <description>Single oral dose of 72 mg of MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E8">
          <title>MK-7252 108 mg</title>
          <description>Single oral dose of 108 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E9">
          <title>MK-7252 120 mg</title>
          <description>Single oral dose of 120 mg of MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E10">
          <title>MK-7252 162 mg</title>
          <description>Single oral dose of 162 mg MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E11">
          <title>MK-7252 180 mg</title>
          <description>Single oral dose of 180 mg of MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E12">
          <title>Placebo</title>
          <description>Single oral dose of placebo to match MK-7252 administered in a fasted state</description>
        </group>
        <group group_id="E13">
          <title>Post-Study</title>
          <description>MK-7252 or placebo as a single dose in the post-study period administered in a fasted state</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Postural orthostatic tachycardia syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mouth swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mucosal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Orthostatic heart rate response increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

